Genitourinary Cancers

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses treatment advancements in small cell urothelial cancer.

PD-1 and PD-L1 inhibitors, including nivolumab, atezolizumab, and avelumab, will likely play a major role as the backbone of combination therapy for patients with renal cell carcinoma (RCC).

Cabozantinib significantly improved progression-free survival versus everolimus in patients with renal cell carcinoma regardless of the degree of metastases, type or number of prior treatments, or patient risk status.

A new drug application has been submitted for cabozantinib as a treatment for patients with advanced renal cell carcinoma who have received one prior therapy.

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, provides advice to community oncologists who are treating patients with renal cell carcinoma.

Gary Kirsh, MD, president of The Urology Group and LUGPA, Kirsh provides insight on treating prostate cancer within the context of urology, as well as the benefits of a multidisciplinary approach.

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the anti–PD-L1 antibody atezolizumab in bladder cancer.

The prognosis for patients with bladder cancer who have progressed after platinum-based chemotherapy is poor, but the results of a phase II study involving an immunotherapy hold promise.

The FDA has approved nivolumab as a treatment for patients with metastatic renal cell carcinoma following prior treatment with an anti-angiogenic therapy.

With several novel therapies approaching regulatory approval, the treatment landscape for renal cell carcinoma is facing a major upheaval.

An FDA panel voted against approval of the immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guérin therapy.

The FDA has assigned a priority review designation to the PD-1 inhibitor nivolumab as a treatment for patients with advanced renal cell carcinoma following prior antiangiogenic therapy.

The dramatic and often practice-changing findings demonstrated by trials of immunotherapies in melanoma and lung cancer may soon be reflected in the treatment of bladder cancer.

Robert Figlin, MD, and Daniel Petrylak, MD, discuss emerging agents in RCC they are excited about and what challenges still remain in treating the disease.